These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 23491460)
1. Combining two multiple sclerosis treatments has no clinical benefit, study finds. Anekwe L BMJ; 2013 Mar; 346():f1719. PubMed ID: 23491460 [No Abstract] [Full Text] [Related]
2. [Pharmacological treatment of multiple sclerosis]. Myhr KM Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616 [TBL] [Abstract][Full Text] [Related]
3. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis. Banwell B; Tremlett H Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408 [No Abstract] [Full Text] [Related]
4. Editorial: the pitfalls of combination therapy. Vermersch P Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074 [No Abstract] [Full Text] [Related]
5. Use of interferon-beta in the treatment of multiple sclerosis. Derwenskus J; Lublin FD Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838 [No Abstract] [Full Text] [Related]
7. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Tan H; Cai Q; Agarwal S; Stephenson JJ; Kamat S Adv Ther; 2011 Jan; 28(1):51-61. PubMed ID: 21153000 [TBL] [Abstract][Full Text] [Related]
8. The use of interferon Beta and glatiramer acetate in multiple sclerosis. Goodin DS Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209 [TBL] [Abstract][Full Text] [Related]
10. Approaches to neuroprotective strategies in multiple sclerosis. Tselis A; Khan OA; Lisak RP Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779 [TBL] [Abstract][Full Text] [Related]
11. 'Time is brain' also in multiple sclerosis. Freedman MS Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740 [No Abstract] [Full Text] [Related]
13. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)]. Federal service on surveillance in healthcare and social development (Roszdravnadzor) Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163 [No Abstract] [Full Text] [Related]
14. A practical approach to immunomodulatory therapy for multiple sclerosis. Burks JS Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681 [TBL] [Abstract][Full Text] [Related]
15. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]. Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317 [No Abstract] [Full Text] [Related]
16. Corticosteroids in combination therapy for multiple sclerosis. Cohen JA Lancet Neurol; 2009 Jun; 8(6):502-3. PubMed ID: 19409855 [No Abstract] [Full Text] [Related]
17. Interferon-beta for multiple sclerosis: Long-term benefits? Rudick RA; Cutter G Ann Neurol; 2007 Apr; 61(4):283-5. PubMed ID: 17444503 [No Abstract] [Full Text] [Related]
18. Combination therapy for treatment of multiple sclerosis. Lublin FD; Reingold SC Ann Neurol; 1998 Jul; 44(1):7-9. PubMed ID: 9667587 [No Abstract] [Full Text] [Related]